Averill Funds Sell $80.4M Veradermics Stock and Exercise 300K Warrants
MANE has more than doubled off its 52-week low of $32.
Summary
Averill Master Fund and Averill Madison Master Fund sold $80.4 million of Veradermics stock and exercised 300,000 pre-funded warrants, adding to recent insider selling pressure.
Key Events · Ownership and Investor Activity · MANE
-
Averill Funds Sell $80.4M
Averill Master Fund sold 690,601 shares and Averill Madison Master Fund sold 59,399 shares on August 19, 2026, at $107.25 per share, totaling approximately $80.4 million.
-
Warrant Exercises Add 300K Shares
On August 20, 2026, Averill Master Fund exercised 149,000 pre-funded warrants and Averill Madison Master Fund exercised 151,000 pre-funded warrants at $0.00001 per share, adding 300,000 shares to the float.
-
Insider Selling Wave Continues
This sale follows $103.1 million in open-market insider selling over the past 90 days, including a $15 million planned sale by CEO Reid Waldman and a $10.7 million sale by Director John W. Childs.
-
Ownership Stakes Reduced
After these transactions, Averill Master Fund holds 3,718,970 shares (8.8%), Averill Madison Master Fund holds 612,033 shares (1.5%), and Montanova Capital reports aggregate beneficial ownership of 3,718,970 shares (8.8%).
Analysis · MANE · Life Sciences
The Averill funds, managed by Montanova Capital, sold 750,000 shares at $107.25 on August 19, 2026, for approximately $80.4 million, and then exercised pre-funded warrants for 300,000 shares at a nominal price on August 20. This continues a wave of insider selling that has totaled over $103 million in the past 90 days, including a $15 million planned sale by the CEO. The warrant exercises add 300,000 shares to the float, increasing potential supply pressure.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29% of the 1483 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $102.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $32.00 to $131.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.